No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Orencia is a biologic drug used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It is a recombinant human monoclonal antibody that works by blocking the activity of a protein called TNF-alpha, which is involved in the inflammation process. Orencia is administered via subcutaneous injection and is available in both a prefilled syringe and a vial.
Orencia is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is currently marketed by Bristol-Myers Squibb, and is available in the United States, Canada, Europe, and other countries.
The Orencia market is highly competitive, with several other biologic drugs available to treat immune disorders. These include Humira, Enbrel, Remicade, and Simponi. In addition, there are several generic versions of Orencia available in some countries.
Companies in the Orencia market include Bristol-Myers Squibb, AbbVie, Pfizer, Merck, and Janssen Pharmaceuticals. Show Less Read more
